← Back to patent-cliff list
Temozolomide
Tier C — Watch / tradeTemozolomide
MSD (Merck Sharp & Dohme)
Originator
1999
First approval
-
Expiry (public)
$0.94B ▲
Peak sales
Small molecule
Type
Targets：DNA
Brand：Temodal, Temodar, Temodex
Indications (approved)：尤因肉瘤, Glioma, Glioblastoma
Regional status
US
Phase III
2006-01-01
EU
Approved
1999-01-26
China
Approved
2004-04-30
Japan
Approved
2006-07-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Temozolomide?
Approved indications include: 尤因肉瘤, Glioma, Glioblastoma.
When does the Temozolomide patent expire?
No public expiry year is available for Temozolomide yet; this page updates once verified.
How do I get a quote for Temozolomide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04